SG Americas Securities’s Taysha Gene Therapies TSHA Stock Holding History

SG Americas Securities’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38M	Sell	202,260 -1,974,482	-91%	-$11.7M	﹤0.01%	1691
2026 Q1	$9.73M	Buy	2,176,742 +1,395,268	+179%	+$6.49M	0.01%	799
2025 Q4	$4.3M	Buy	781,474 +748,525	+2,272%	+$3.63M	0.01%	1151
2025 Q3	$108K	Sell	32,949 -460,352	-93%	-$1.3M	﹤0.01%	3051
2025 Q2	$1.14M	Buy	+493,301	New	+$1.07M	﹤0.01%	1092
2025 Q1	–	Sell	-28,498	Closed	-$49K	–	3768
2024 Q4	$49K	Sell	28,498 -35,486	-55%	-$73.6K	﹤0.01%	2910
2024 Q3	$129K	Buy	+63,984	New	+$140K	﹤0.01%	2848
2021 Q4	–	Sell	-9,168	Closed	-$171K	–	3811
2021 Q3	$171K	Buy	+9,168	New	+$174K	﹤0.01%	3337

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SG Americas Securities's TSHA Position: Q2 2026 in Review

SG Americas Securities reduced its Taysha Gene Therapies (TSHA) stake by 91% in Q2 2026, selling an estimated $11.7M and leaving 202,260 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1691.

SG Americas Securities first reported a position in TSHA in Q3 2021 and has held it in 8 quarters since. The position peaked at $9.73M in Q1 2026. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

SG Americas Securities held 202,260 shares of Taysha Gene Therapies worth $1.38M as of Q2 2026.
SG Americas Securities sold 1,974,482 Taysha Gene Therapies shares in Q2 2026, an estimated $11.7M.
Taysha Gene Therapies made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1691 holding.
SG Americas Securities first reported a position in Taysha Gene Therapies in Q3 2021 and has held it in 8 quarters since.
SG Americas Securities's Taysha Gene Therapies position peaked at $9.73M in Q1 2026.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.